Satsuma Pharmaceuticals, Inc. Common Stock

STSA

Capitalización de mercado USD 36.5 M

Acerca de: Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Empleados: 25